Bahl, Amit <br/><br/>
Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279).  [electronic resource] 

 -  BJU international  Dec 2015 
 - 880-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article 
<br/><br/><label>ISSN: </label>1464-410X 
<br/><br/><label>Standard No.: </label>10.1111/bju.13069  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--adverse effects<br/>Humans<br/>Male<br/>Middle Aged<br/>Patient Safety<br/>Prostatic Neoplasms, Castration-Resistant--drug therapy<br/>Quality of Life<br/>Taxoids--adverse effects<br/>United Kingdom--epidemiology